Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950101 | 0.77 | IDO1 (0.34) | — | |
| SCHEMBL292398 | 0.75 | CYP1A2 (0.40) | CYP1A2CYP2A6CYP2C19TNKS2ALDH1A1 | |
| SCHEMBL11265175 | 0.72 | CYP1A2 (0.38) | CYP1A2CYP2A6CYP2C19TNKS2ALDH1A1 | |
| SCHEMBL16426466 | 0.72 | CYP1A2 (0.38) | CYP1A2CYP2A6CYP2C19TNKS2ALDH1A1 | |
| SCHEMBL5746244 | 0.69 | HTT (0.36) | CYP1A2ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL3120897 | 0.67 | HPRT1 (0.45) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL2455965 | 0.67 | CYP1A2 (0.31) | CYP1A2HPGDHSD17B10 | |
| SCHEMBL328776 | 0.66 | HPRT1 (0.48) | CYP1A2CYP2A6CYP2C19ALDH1A1HPGD | |
| SCHEMBL8651623 | 0.66 | SENP2 (0.35) | CYP1A2CYP2A6CYP2C19TNKS2ALDH1A1 | |
| SCHEMBL66086 | 0.65 | CYP1A2 (0.39) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | CYP1A2 972/4885CYP2A6 572/4885CYP2C19 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.